Atara Biotherapeutics, Inc.
ATRA
$7.32
-$0.28-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 670.30% | 1,779.79% | 2,892.69% | 2,131.40% | 1,823.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 670.30% | 1,779.79% | 2,892.69% | 2,131.40% | 1,823.98% |
| Cost of Revenue | -24.66% | -13.41% | -36.30% | -29.30% | -21.39% |
| Gross Profit | 93.56% | 80.24% | 84.57% | 72.62% | 28.22% |
| SG&A Expenses | -9.13% | -14.91% | -33.17% | -29.44% | 5.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.86% | -13.66% | -35.73% | -29.33% | -17.58% |
| Operating Income | 77.10% | 68.75% | 74.97% | 64.66% | 23.43% |
| Income Before Tax | 78.97% | 68.59% | 73.21% | 57.55% | 18.95% |
| Income Tax Expenses | -272.73% | 10.53% | -- | 9.09% | 450.00% |
| Earnings from Continuing Operations | 79.00% | 68.61% | 73.21% | 57.53% | 18.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.00% | 68.61% | 73.21% | 57.53% | 18.94% |
| EBIT | 77.10% | 68.75% | 74.97% | 64.66% | 23.43% |
| EBITDA | 78.68% | 69.99% | 76.44% | 65.96% | 23.78% |
| EPS Basic | 91.52% | 82.11% | 81.67% | 68.60% | 22.65% |
| Normalized Basic EPS | 90.45% | 82.10% | 82.01% | 73.29% | 25.24% |
| EPS Diluted | 91.52% | 82.11% | 81.67% | 68.60% | 22.65% |
| Normalized Diluted EPS | 90.45% | 82.10% | 82.01% | 73.29% | 25.24% |
| Average Basic Shares Outstanding | 147.61% | 75.42% | 46.12% | 35.22% | 4.80% |
| Average Diluted Shares Outstanding | 147.61% | 75.42% | 46.12% | 35.22% | 4.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |